Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review: assessment group report
Assessment group report impact of decision support unit report health assessment questionnaire (HAQ) progression on clinical and cost effectiveness
Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review: assessment group report
17 March 2015 (376.92 Kb 49 sec) |
This page was last updated: 18 March 2015